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Agonistic monoclonal antibodies (mAbs) targeting the co-stimulatory receptor 4-1BB are
among the most effective immunotherapeutic agents across pre-clinical cancer models.
However, clinical development of full-length 4-1BB agonistic mAbs, has been hampered
by dose-limiting liver toxicity. We have previously developed an EGFR-targeted 4-1BB-
agonistic trimerbody (1D8N/CEGa1) that induces potent anti-tumor immunity without
systemic toxicity, in immunocompetent mice bearing murine colorectal carcinoma cells
expressing human EGFR. Here, we study the impact of human EGFR expression on
mouse liver in the toxicity profile of 1D8N/CEGa1. Systemic administration of IgG-based
anti-4-1BB agonist resulted in nonspecific immune stimulation and hepatotoxicity in a
liver-specific human EGFR-transgenic immunocompetent mouse, whereas in
1D8N/CEGa1-treated mice no such immune-related adverse effects were observed.
Collectively, these data support the role of FcgR interactions in the major off-
tumor toxicities associated with IgG-based 4-1BB agonists and further validate the
safety profile of EGFR-targeted Fc-less 4-1BB-agonistic trimerbodies in systemic
cancer immunotherapy protocols.
Keywords: cancer immunotherapy, immunostimulatory antibodies, 4-1BB agonists, hepatotoxicity, trimerbodies,
EGFR, EGFR-targeted 4-1BB agonistsorg January 2021 | Volume 11 | Article 6143631
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The success of immune checkpoint blockade using PD-1/PD-
L1 and/or CTLA-4 inhibitors has validated the concept of
immunomodulating monoclonal antibodies (mAbs) as a
powerful therapeutic strategy, but responses are still limited
to a minor fraction of cancer patients (1). Immune cell
stimulation by agonistic mAbs acting on co-stimulatory
receptors, such as CD40, OX40, and 4-1BB, is a particularly
interesting approach, as these receptors are mainly expressed
on T cells upon activation (2, 3). 4-1BB (CD137, TNFRSF9) is a
member of the tumor necrosis factor receptor superfamily
(TNFRSF) that is transiently expressed following activation
through the T cell receptor (TCR) (4). To date, a unique
ligand for 4-1BB has been identified, 4-1BBL (TNFSF9),
which is expressed on the surface of antigen-presenting cells
(5). 4-1BBL trimerization leads to 4-1BB receptor clustering
and TRAFs-mediated activation of NF-kB andMAPK intracellular
signaling cascades leading to enhanced T cell proliferation
and survival (6).
However, off-tumor toxicities have been the major
impediment to the clinical development of first-generation
IgG-based 4-1BB agonistic mAbs. The fully human IgG4
urelumab caused dose-dependent liver toxicity, including
two fatalities (7, 8). Additional studies have shown that
dose reduction ameliorated liver toxicity, but also resulted
in limited clinical activity (8). The fully human IgG2
utomilumab displayed a better safety profile but is a relatively
less potent 4-1BB agonist (9). Therefore, new strategies are
being developed to preserve the anti-tumor effect avoiding off-
tumor toxicities associated with FcgR interactions (10–12).
These approaches aim to confine 4-1BB co-stimulation to the
tumor microenvironment.
We have recently described a novel EGFR-targeted Fc-less 4-
1BB agonistic trimerbody (1D8N/CEGa1), which is a potent
costimulator in vitro and exhibits enhanced tumor penetration
and powerful anti-tumor activity in immunocompetent mice
bearing gene-modified CT26 colorectal carcinoma cells
expressing human EGFR (10). In this model, the anti-tumor
effect of the bispecific trimerbody was dependent on human
EGFR expression (13), but the potential toxicity profile was
dictated by the endogenous mouse EGFR. In this context, the
1D8N/CEGa1 trimerbody did not induce the systemic cytokine
production and hepatotoxicity associated with IgG-based 4-1BB
agonists (10). To further investigate this aspect and given that the
anti-EGFR EGa1 VHH single-domain antibody was isolated from
a phage-displayed llama VHH library immunized with EGFR-
positive human cells (14, 15), we studied here the impact of
human EGFR expression on the liver in the 1D8N/CEGa1 toxicity
profile in a liver-specific huEGFR-transgenic immunocompetent
mouse (16). In this model, systemic administration of IgG-based
anti-4-1BB agonist resulted in nonspecific immune stimulation
and liver toxicity, whereas treatment with the EGFR-targeted 4-
1BB-agonistic trimerbody lacked these immune-related
side effects.Frontiers in Immunology | www.frontiersin.org 2METHODS
Mice
C57BL/6 wild-type (WT) female mice and transgenic Alb-D654–
1186huEGFR (DEGFR-tg) (16) littermates were housed in the
animal facility of the Instituto de Investigaciones Biomédicas
“Alberto Sols” (IIBm) (CSIC-UAM, Madrid, Spain). Animals
were kept in controlled conditions of temperature (21 ±
1°C), humidity (50 ± 5%), and 12 hours light/dark cycles.
Manipulation was performed in laminar flow hood, when
necessary, and sterilized water and food were available ad
libitum All animal procedures conformed to European Union
Directive 86/609/EEC and Recommendation 2007/526/
EC, enforced in Spanish law under RD 1201/2005. Animal
protocols were approved by the Animal Experimentation Ethics
Committee of the IIBm, and the Animal Welfare Division of the
Environmental Affairs Council of the Government of Madrid (66/
14, 118/19).
Cells and Culture Conditions
HEK293 (CRL-1573) cells were obtained from the American
Type Culture Collection and mouse CT26 cells (CRL-2638)
expressing human EGFR (CT26huEGFR) or infected with the
empty vector retrovirus (CT26mock) were provided by Dr M.
Rescigno (European Institute of Oncology, Milan) (13). The cells
were grown in complete Dulbecco’s modified Eagle’s medium
(DMEM) (Lonza) supplemented with 2 mM L-glutamine, 10%
(vol/vol) heat-inactivated Fetal Calf Serum (FCS), and antibiotics
(100 units/mL penicillin, 100 mg/mL streptomycin) (all from
Life Technologies) referred as to DMEM complete medium
(DCM), unless otherwise stated. The cell lines were routinely
screened for mycoplasma contamination by PCR (Stratagene).
Hepatocyte Isolation and Culture
Hepatocytes were isolated as previously described following the
two-step collagenase perfusion technique followed by isodensity
purification in a Percoll gradient (17). Briefly, livers from 3
months-old mice were perfused with Hanks´ balanced salt
solution supplemented with 10 mM Hepes and 0.2 mM EGTA
for 5 min, followed by a perfusion (10–15 min) with William´s E
medium containing 10mM Hepes and 0.03% collagenase I
(Worthington). Livers were further minced, and viable
hepatocytes were selected by centrifugation in Percoll and
seeded in collagen I-coated plates (5 µg/sq cm) at a density of
28 x 103/cm2 in Dulbecco´s modified Eagle´s medium/F-12 (1:1)
supplemented with 10% serum.
Expression and Purification of
Recombinant Antibodies
The 1D8N/CEGa1 trimerbody was produced in stably
transfected HEK293 cells (10) cultured in complete DMEM with
500 mg/mL G418 (all from Life Technologies), and conditioned
medium purified using the (Twin-)Strep-tag purification system
(IBA Lifesciences) connected to an ÄKTA Prime plus system
(GE Healthcare). The purified antibody was dialyzed overnight atJanuary 2021 | Volume 11 | Article 614363
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under reducing conditions and stored at 4°C. Purified antibodywas
tested for endotoxin levels by Pierce´s limulus amebocyte lysate
(LAL) chromogenic endotoxin quantitation kit, following the
manufacturer’s specifications (Thermo Fisher Scientific).
Endotoxin levels of purified antibody stocks were lower than 0.25
EU/ml as determined by LAL test. Purified anti-mouse 4-1BB IgG
(clone 3H3) was purchased from (cat#BE0239, BioXCell).
ELISA
Purified mouse 4-1BB:hFc chimera (mo4-1BB), mouse EGFR:
hFc (moEGFR) and human EGFR:hFc chimera (huEGFR) (all
from R&D Systems) were immobilized at 3 µg/ml on Maxisorp
ELISA plates (NUNC Brand Products) overnight at 4 °C. After
washing and blocking with 200 µl PBS 5% BSA (Merck Life
Science), 100 µl of purified 3H3 IgG or 1D8N/CEGa1 trimerbody
were added and incubated for 1 hour at room temperature. The
wells were washed for three times with PBS 0.05% Tween-20, and
100 µl of anti-FLAG mAb (clone M2; mIgG1; cat#F1804, Merck
Life Science) were added for 1 hour incubation at room
temperature. The plate was washed as above and 100 µl of
HRP-conjugated goat anti-rat IgG or HRP-conjugated goat
anti-mouse IgG (both from Merck Life Science) were added to
wells previously incubated with 3H3 IgG or 1D8N/CEGa1
trimerbody, respectively. Afterwards, the plate was washed and
developed using OPD (Merck Life Science).
Biolayer Interferometry
All biolayer interferometry was performed on an Octet RED96
(Fortebio). To investigate the binding of 1D8N/CEGa1 to hu-EGFR
ormoEGFR,30nMofhuEGFRormoEGFR in fusionwithahuman
Fc region were immobilized onto AHC biosensors (Fortebio)
coated with anti-human Fc antibodies for 20 min, in 20 mM
HEPES, 150 mM NaCl pH 7.4 buffer (HBS). Then, biosensors
were moved into 20 nM 1D8N/CEGa1 in HBS and association was
measured for 20 min followed by one hour of dissociation in HBS.
To investigate the binding of hu-EGFR or moEGFR in solution to
immobilized 1D8N/CEGa1, biosensors coated with mo4-1BB in
fusion with a human Fc region were prepared using amine
reactive chemistry. Briefly, AR2G biosensors (Fortebio) were
activated with s-NHS/EDC, coated with 2 µg mouse 4-1BB per
biosensor at pH 6 for 20 min, and quenched with ethanolamine.
Then, 10 nM of 1D8N/CEGa1 in HBS was immobilized onto the
biosensors for 30 min. Human or moEGFR (50 nM in HBS) was
then introduced and allowed to associate for 20 min and dissociate
for one hour. In both experiments, a reference biosensor coated and
immobilized with the same ligands, but not receiving the
experimental analyte proteins, was subtracted from the other
sensorgrams prior to data analysis. Data were fit to 1:1 binding
models using the Octet Data Analysis software (Fortebio). In
the case of moEGFR’s binding to immobilized 1D8N/CEGa1,
fitting included only its initial association phase, due to its
biphasic binding.
Flow Cytometry
The cell surface expression of EGFR was analyzed on freshly-
isolated liver cells from C57BL/6 WT and EGFR-tg mice, and onFrontiers in Immunology | www.frontiersin.org 3CT26mock and CT26huEGFR cells after incubation for 30 min with
the human EGFR-specific chimeric mouse/human IgG1
cetuximab (Merck KGaA), or the purified 1D8N/CEGa1
trimerbody. After washing, cells were treated with appropriate
dilutions of phycoerytrin (PE)-conjugated goat anti-human IgG
F(ab′)2 (Fc specific; cat#109-116-097, Jackson Immuno
Research), or anti-FLAG mAb (clone M2), and then with PE-
conjugated goat anti-mouse IgG F(ab’)2 antibody (cat#115-116-
072, Jackson Immuno Research). Samples were analyzed with a
MACSQuant Analyzer 10 flow cytometer (MiltenyiBioteh). A
minimum of 20,000 events were acquired for each sample and
data were evaluated using FCS Express V3 software (De
Novo Software).
Toxicity Studies
Eight weeks old C57BL/6 wild-type and DEGFR-tg littermates
received a weekly i.p. dose of 3H3 IgG or 1D8N/CEGa1 (6 mg/kg)
for 3 weeks. Mice were anesthetized and bled on days 0, 7, 14,
and 21. To obtain mouse serum, blood was incubated in BD
microtainer SST tubes (BD Biosciences), followed by
centrifugation. Serum was stored at −20 °C until use. Serum
levels of alanine aminotransferase (ALT) were determined at
day 14 using Reflotron GPT/ALT strips and the Reflotron
plus analyzer (Roche Diagnostics). One week after the last
dose of antibodies, mice were euthanized and the liver and
spleens, were surgically removed, weighted, and fixed in 10%
paraformaldehyde for 48 h. Then fixed tissues were washed and
embedded in paraffin. Tissue sections (5 µm) were stained with
hematoxylin and eosin. Lymphocyte infiltration in the liver was
quantified using the ImageJ software.
Histological Studies
Tissue samples were fixed in 10% neutral buffered formalin (4%
formaldehyde in solution), paraffin-embedded and cut at 3 mm,
mounted in superfrost® plus slides and dried overnight. For
different staining methods, slides were deparaffinized in xylene
and re-hydrated through a series of graded ethanol until water.
Consecutive sections for several immunohistochemistry
reactions were perform in an automated immunostaining
platform (Ventana Discovery XT, Roche; AS Link, Dako,
Agilent). Antigen retrieval was first performed with the
appropriate pH buffer, (CC1m, Ventana, Roche; Low pH
buffer, Dako, Agilent) and endogenous peroxidase was blocked
(peroxide hydrogen at 3%). Then, slides were incubated with the
appropriate primary antibody as detailed: rabbit monoclonal
anti-EGFR (mouse preferred) (D1P9C, 1/600, Cell Signaling,
#71655) and mouse monoclonal anti-huEGFR (EGFR.113, 1/10,
Leica, NCL-EGFR). After the primary antibody, slides were
incubated with the corresponding visualization systems
(OmniMap anti-Rabbit, Ventana, Roche; EnVisionFLEX+
Mouse Linker, Dako, Agilent) conjugated with horseradish
peroxidase. Immunohistochemical reaction was developed
using 3, 30-diaminobenzidine tetrahydrochloride (ChromoMap
DAB, Ventana, Roche; FLEX DAB, Dako, Agilent) and nuclei
were counterstained with Carazzi’s hematoxylin. Finally, the
slides were dehydrated, cleared and mounted with a permanent
mounting medium for microscopic evaluation. Positive controlJanuary 2021 | Volume 11 | Article 614363
Compte et al. Case Report: Non-Toxic EGFR-Targeted 4-1BB Immunotherapysections known to be primary antibody positive were included
for each staining run. Whole slides were acquired with a slide
scanner (AxioScan Z1, Zeiss).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
Software version 6.0. Data is presented as mean ± SD.
Significant differences (P value) were discriminated by applying
a two-tailed, unpaired Student’s t test assuming a normal
distribution. P values are indicated in the corresponding
figures for each experiment.RESULTS AND DISCUSSION
The 1D8N/CEGa1 Trimerbody Binds to
Human EGFR With a Higher Affinity Than
to Mouse EGFR
The EGa1 is a well characterized EGFR-specific VHH that was
generated from a phage-displayed llama VHH library after
immunizing and screening with EGFR-positive human cells
(14, 18). Binding studies using biolayer interferometry were
used to compare the binding of EGa1VHH to human and
mouse EGFR when integrated in a multichain bispecific anti-4-
1BB x anti-EGFR trimerbody format (Figure S1) (10). These
interactions were investigated in two orientations, either with
biosensor-immobilized EGFR and 1D8N/CEGa1 in solution
(Figure 1A), or immobilized 1D8N/CEGa1 and EGFR inFrontiers in Immunology | www.frontiersin.org 4solution (Figure 1B). In both orientations, the interaction
between 1D8N/CEGa1 and human EGFR (huEGFR) dissociated
much more slowly than the interaction between 1D8N/CEGa1
and mouse EGFR (moEGFR); for biosensor-immobilized EGFR
and 1D8N/CEGa1 in solution, the interaction half-lives were ~36
hours and ~40 min for human and mouse EGFR, respectively,
while for the reversed orientation, the half-lives were ~20 and ~1
min (Figure 1C). The difference in measured dissociation rates
in the two orientations probably reflects differences in avidity
due to trivalent binding by 1D8N/CEGa1 and bivalent binding by
EGFR (fused to a human Fc region). A comparison of the
primary sequence of huEGFR and moEGFR showed that
EGa1’s epitope, as seen in the 4KRO crystal structure (19), is
mostly conserved, with four differing residues around the
periphery of the epitope (Figure 1D). This is consistent with
the lower affinity of EGa1 for moEGFR determined by these
binding studies.
The 1D8N/CEGa1 Trimerbody Shows
Negligible Toxicity in Immunocompetent
Transgenic Mice Expressing Human EGFR
in the Liver
Transgenic Alb-D654–1186EGFR mice (from now abbreviated as
DEGFR-tg) are immunocompetent animals expressing an
hepatocyte-specific truncated form of the human EGFR that
lacks the intracellular catalytic domain (amino acids 654–1186)
(16). Liver paraffin sections from wild-type C57BL/6 (WT) and
DEGFR-tg mice were stained with moEGFR-specific andA B
DC
FIGURE 1 | Biolayer interferometry investigating the binding of 1D8N/CEGa1 to human and mouse EGFR. (A) Human EGFR (huEGFR) and mouse EGFR (moEGFR),
both in fusion with a human Fc region, were immobilized onto biosensors coated with anti-human Fc antibodies prior to the experiment. 20 nM of 1D8N/CEGa1
associated with the biosensors for 20 min, followed by one hour of dissociation. Duplicate biosensors are shown, along with theoretical binding curves for the kinetic
rate constants obtained by fitting. (B) 10 nM of 1D8N/CEGa1 was immobilized to biosensors coated with mouse 4-1BB for 30 min, after which 50 nM of human or
mouse EGFR (both in fusion with a human Fc region) associated for 20 min and dissociated for one hour. Theoretical binding curves are shown; note that fitting to
mouse EGFR’s association step was limited to the first binding phase, due to its heterogeneous binding. (C) Kinetic rate constants and dissociation constants were
obtained by fitting of the experimental binding data from panels (A, B) to 1:1 binding models. In both experiments, 1D8N/CEGa1 dissociates more rapidly from
moEGFR than from huEGFR. (D) The crystal structure of the EGa1 VHH bound to human EGFR (PDB 4KRO), shown with and without the EGa1 VHH. Residues of
EGFR that are conserved between huEGFR and moEGFR are colored white, while similar residues are yellow, dissimilar residues are red, and glycans are green.
Differing residues in proximity to EGa1 are labeled with the murine residue in parenthesis.January 2021 | Volume 11 | Article 614363
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showed moEGFR expression on the entire surface of the
cytoplasmic membrane with a strong and uniform intensity in
most of the liver lobules (Figure S2). In DEGFR-tg mice,
hepatocytes showed a partial and segmental expression of
huEGFR in the cytoplasmic membrane with a strong intensity
distributed in segments or areas of different sizes, sometimes
exhibiting a punctiform pattern, especially in centrilobularFrontiers in Immunology | www.frontiersin.org 5hepatocytes (Figure 2B). Periportal and midzonal hepatocytes
displayed also huEGFR expression albeit at a lesser extent
(Figure 2B). No expression of huEGFR was detected in WT
mice (Figure 2A). These findings were further confirmed by flow
cytometry, where it was also found that about 25% of freshly
isolated primary hepatocytes from DEGFR-tg mice expressed
significant levels of cell surface huEGFR (Figure 2C), and that
the 1D8N/CEGa1 trimerbody is more efficient in recognizingA B
C
FIGURE 2 | Analysis of human EGFR expression by IHC in liver sections from (A) WT C57BL/6 and (B) DEGFR-tg mice. Representative micrographs of liver
sections from the indicated mice showing human EGFR staining in brown. Nuclei are counterstained with hematoxylin. Scale bars, 200 µm (upper images); and 20
µm (middle and lower images). Upper panels show panoramic views of the corresponding mouse livers, and middle and lower panels are higher magnification
images of centrilobular (zone 3) and periportal areas (zone 1), respectively, corresponding to zones indicated by black boxes in the upper images. (C) Flow cytometry
analysis of EGFR expression in primary hepatocytes freshly isolated from WT C57BL/6 and DEGFR-tg mice (right panels) or CT26mock and CT26huEGFR cells (left
panels). Cells incubated with isotype control antibodies are shown as grey-filled histogram. Fluorescence intensity (abscissa) is plotted against relative cell number
(ordinate). The numbers indicate the percentage of EGFR-positive cells.January 2021 | Volume 11 | Article 614363
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mice (Figure 2C).
We compared the toxicity profile of the 1D8N/CEGa1
trimerbody with that of the well-characterized anti-4-1BB
agonistic 3H3 IgG (4) in WT and DEGFR mice injected (6 mg/
kg) i.p. once a week for 3 weeks and euthanized 1 week later. As
shown in Figure 3A, treatment of DEGFR-tg mice with 3H3 IgG
resulted in significant enlargement of the spleen as demonstratedFrontiers in Immunology | www.frontiersin.org 6by weight (P = 0.0008). In contrast, treatment with 1D8N/CEGa1
did not result in splenomegaly or hepatomegaly (Figure 3A).
The histologic study of the liver of mice treated with 3H3 IgG
revealed significant mononuclear cell infiltration, forming
periportal cuffs with thickening of tunica media and also
infiltration foci associated with microvasculature, while no
significant infiltration was observed in mice treated with




FIGURE 3 | Treatment with 1D8N/CEGa1 does not induce toxicity. (A) Liver and spleen weights from WT and DEGFR-tg mice littermates (n = 3–5/group) treated
with PBS, 3H3 IgG, or 1D8N/CEGa1. (B) Hematoxylin and eosin staining of representative tissue slides from the liver, and spleen of mice treated with PBS, 3H3 IgG,
and 1D8N/CEGa1. Scale bars are shown. (C) Quantification of the mononuclear cell infiltrated surface in the liver of WT (n = 3 per treatment) and DEGFR-tg (n = 5
per treatment) littermates treated with PBS, 3H3 IgG, or 1D8N/CEGa1. (D) Serum ALT levels in response to the treatments with 3H3 IgG and 1D8N/CEGa1. The ratio
of ALT activity of WT and DEGFR-tg mice treated with 3H3 IgG or 1D8N/CEGa1 vs. the ALT activity of WT and DEGFR-tg mice treated with PBS at day 14 of
treatments is shown (n = 3/5 per treatment). (E) Sera from WT and DEGFR-tg mice were collected from peripheral blood at days 0, 7, and 21 of treatment, and
levels of IFNg were measured by ELISA (n = 3 per time point). Results represent 2 separate experiments. All data are presented as mean ± SD. P values were
calculated with Student’s t test.January 2021 | Volume 11 | Article 614363
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DEGFR-tg mice treated with 3H3 IgG, while it only represented
0.06% in mice treated with 1D8N/CEGa1 (P = 0.0026) or PBS (P =
0.0026) (Figure 3C). Consistent with these results, we observed a
2-fold increase in alanine transaminase (ALT) levels in the serum
of WT and DEGFR-tg mice treated with 3H3 IgG compared to
mice of the same genotype treated with PBS. In contrast, mice
treated with 1D8N/CEGa1 showed little or no increase in ALT
levels (Figure 3D). The effect of treatment with 3H3 IgG or
1D8N/CEGa1 on the levels of IFNg in serum was also compared.
3H3 IgG treatment triggered significant elevation of IFNg at
days 7 and 21 in both WT and DEGFR-tg mice (Figure 3E). In
contrast, 1D8N/CEGa1 induced levels of IFNg comparable to
PBS-treated mice in both groups.
In summary, we demonstrated that treatment of DEGFR-tg
mice with the strong 4-1BB-agonistic 3H3 IgG induced a toxicity
profile similar to that observed in WT C57BL/6 mice, with
significant immune cell infiltration and systemic inflammation,
indicating the suitability of the model to study 4-1BB–related
toxicity. In contrast, none of these features were observed in
DEGFR-tg mice treated with the 1D8N/CEGa1 trimerbody,
despite the expression of both huEGFR and moEGFR on the
hepatocyte surface, which excludes that the lower affinity of
1D8N/CEGa1 for moEGFR may be responsible for the absence of
liver toxicity observed in WT mice. These results further support
the role of FcgR interactions in the 4-1BB-agonist-associated
immunological abnormalities and organ toxicities (20–22) and
confirm the safety profile of EGFR-targeted 4-1BB-agonistic
trimerbodies in systemic cancer immunotherapy protocols.DATA AVAILABILITY STATEMENT
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